Quantcast

Latest European Association for the Study of Diabetes Stories

2010-09-22 06:00:00

RIDGEFIELD, Conn., Sept. 22 /PRNewswire/ -- New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients,(1) and when administered as monotherapy in T2D patients for whom metformin is inappropriate.(2) In addition, new pharmacokinetic (PK) data demonstrate that decreases in renal...

2010-09-20 07:30:00

PARIS, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus® (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral antidiabetic drug therapy...

2010-07-01 15:00:00

DANBURY, Conn., July 1 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following abstracts describing results from studies of the company's product candidates have been accepted for presentation in September during the 46th annual meeting of the European Association for the Study of Diabetes in Stockholm. Oral Presentation: #OP 01, Oral session on novel formulations and delivery of insulin, Tuesday, September 21, 2010 10:45 AM - 12:15 PM "A novel pH-neutral...

2009-06-29 10:20:00

JACKSONVILLE, Fla., June 29 /PRNewswire-USNewswire/ -- On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine (Lantus, sanofi-aventis) and the development of certain malignancies. The authors themselves, and the accompanying editorial, cautioned against over-interpretation of their limited data and analyses, which precluded them from drawing any firm...

22ff9fa3021d1baf99d2399448b608a01
2009-06-27 15:06:42

The European Association for the Study of Diabetes (EASD) has announced a discovered link between French drug maker Sanofi-Aventis' Lantus diabetes drug and cancer. The EASD cited the findings of four studies found in the journal Diabetologia. Experts admit the results were "far from conclusive but they do indicate the need for further investigation of this issue." According to Reuters, Sanofi earned about 2.45 billion euros ($3.4 billion) from Lantus, also known as glargine, in 2008. The...

2008-10-30 09:00:00

WORCESTER, Mass., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today commented on the consensus algorithm for Type 2 diabetes treatment issued by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published online on October 22, 2008 (Diabetes Care, volume 31, number 12, December 2008). A...

2008-10-22 12:00:51

A panel of experts convened by the American Diabetes Association and the European Association for the Study of Diabetes has issued updated treatment recommendations for type 2 diabetes, in a consensus statement being published online today in the journals Diabetes Care and Diabetologia. The revisions to the diabetes treatment algorithm, first published in 2006, provide guidance to health care providers for treating type 2 diabetes, taking into account new medications that have come on the...

2008-09-10 12:00:52

PARIS, September 10 /PRNewswire-FirstCall/ -- - Abstracts 186 and 1003 Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin regimen with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and rapid-acting APIDRA(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) produced...

2008-09-08 03:00:25

At the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome, Biodel Inc. (Nasdaq: BIOD) today reported results from its two pivotal Phase III clinical trials designed to compare the efficacy and safety of VIAject(TM) to Humulin(R) R, a regular human insulin (RHI), in the treatment of patients with Type 1 and Type 2 diabetes. The primary objective of the trials was to determine if VIAject(TM) is non- inferior to RHI in the management of blood glucose levels,...

2008-09-05 09:00:37

44th Annual Meeting of the European Association for the Study of Diabetes Rome, Italy, September 6 - 11, 2008 WORCESTER, Mass., Sept. 5, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, will present study results at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD,...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related